Physician profile

Chet Hammill

Surgery · Portland, OR

NPI 1720283310

$17,345.02

in general payments reported to CMS, 2019-2025

9 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Consulting Fee$12,812.87
Food and Beverage$13.05

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Ethicon US, LLC $6,525.92 2023 Enseal, Echelon; Endopath, Stratafix
Bk Medical Holding Company INC. $6,300.00 2024 Bk3000, Bk3500 & Bk5000 Ultrasound System
Intuitive Surgical, INC. $3,094.93 2019-2022
Covidien Lp $1,256.00 2019
Analogic Corporation $70.80 2019
Stryker Corporation $27.83 2019
Medtronic, INC. $26.32 2022
Angiodynamics, INC. $24.21 2019
Northgate Technologies, INC. $19.01 2021

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Chet Hammill

$17,345.02

in general payments reported 2019-2025

Years
2019-2024
Top company
Ethicon US, LLC

https://glasscript.com/doctor/213884/chet-hammill

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.